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3300€/QALY for PEG. GUIDE saved 3950€ per patient. Moving
from GUIDE to PEG was associated with an ICER >100,000
EUR/QALY. CONCLUSIONS: Administering combination
therapy with peginterferon alfa-2b and ribavirin in accordance
with the new German guidelines should allow tailoring treatment
efﬁciently to HCV genotype, body weight, and early viral
response in patients with minimal loss of effectiveness. Antiviral
treatment according to the new German guidelines and should
be cost-effective compared to other well-accepted medical 
interventions.
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OBJECTIVES: To assess the efﬁciency of long-term prophylaxis
with oral valganciclovir versus sequential intravenous/oral gan-
ciclovir in the prevention of cytomegalovirus (CMV) infection
and disease in solid organ transplant recipients. METHODS: A
cost minimization analysis was performed from the perspective
of the Spanish National Health System and differential direct
medical costs between both treatments were considered. The efﬁ-
cacy data of valganciclovir regime was obtained from Paya et
al.’s clinical trial (Am J Transplant 2004:611–20). It was con-
ducted a literature review of published clinical trials in order to
obtain the efﬁcacy data of high-risk transplant patients (D+R-)
treated with sequential intravenous/oral ganciclovir. Resource
use, including medication, in the prophylactic treatment with
intravenous/oral ganciclovir were retrieved from published liter-
ature and a retrospective review of 83 clinical charts of kidney,
liver and lung transplant patients in 9 Spanish hospitals. The
resources used with valganciclovir were retrieved from Paya et
al.’s clinical trial. The unit costs of resources were obtained from
national databases (2003€). The results of the study were
expressed in terms of average cost per patient treated with intra-
venous/oral ganciclovir and valganciclovir. RESULTS: At 12
months post-transplantation, the incidence rate of CMV infec-
tion and disease of high risk transplant patients of both long-
term prophylactic regimes were comparable (Kletzmayr J et al.
Transplantation 2000;70:1174–80; Paya et al. 2004). The
average cost of patient treated with valganciclovir and sequen-
tial intravenous/oral ganciclovir was 3295.9€ and 3715.51€,
respectively. The higher overall costs of intravenous/oral ganci-
clovir therapy, compared to oral valganciclovir are due to higher
drug administration costs. CONCLUSIONS: Long-term pro-
phylaxis with oral valganciclovir is a cost-saving option com-
pared to sequential intravenous/oral ganciclovir with similar
efﬁcacy rates, thus the oral therapy is a more efﬁcient strategy
in the prevention of CMV infection and disease in solid organ
transplantation.
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OBJECTIVES: To describe the changes in costs of care for HIV-
positive patients in Italy resulting from the diffusion of new anti-
retroviral combination therapies (HAART). METHODS: In all,
5422 patients from the I.CO.N.A. cohort (Italian Cohort Naive
Antiretrovirals) were followed between 1997 and 2002. This
multi-centric observational study includes adult HIV patients
naïve to antiretroviral therapies. Costs included antiretroviral
therapies (ART), hospital admissions, prophylaxis and treat-
ments for opportunistic infections, and main immuno-virologi-
cal exams. The perspective was that of the National Health
Service. Costs calculated retrospectively and expressed in con-
stant 1997 prices. RESULTS: In the 6-year period considered,
the number of AIDS Deﬁning Events per person-year decreased
from 106 to 26 per thousand, and the number of deaths per
person-year fell from 29 to 8 per thousand. Similarly, hospital-
izations decreased from an annual average of 9.6 days of admis-
sion per patient in 1997 to 0.9 days in 2002. Consequently,
admission costs per person-year decreased from 2.148 euro in
1997 to 256 in 2002, while the average annual costs of ART
increased from 2.145 to 3.149 euro. In only 2 years (from 1997
to 1999), ART costs increased from 42.3% to 85.9% of the total,
while admission costs decreased from 42.3% to 7% and pro-
phylactic treatments from 7.3% to 1.7%. The breakdown of
ART costs shows dual therapies (still widespread at the begin-
ning of the observation period) decreased over time in favor of
HAART, falling from 26.8% in 1997 to 5.9% in 2002. Patients
with fewer than 5 treatment switches had lowest costs distribu-
tions over the entire observation period. CONCLUSIONS: From
1997 to 2002 inpatient costs progressively decreased in favor of
antiretroviral therapy. Annual average costs per patient also
decreased, while total direct costs increased over time: health
resources, ﬁrst concentrated on hospitalized patients were then
distributed over a growing number of subjects.
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OBJECTIVES: When to initiate antiretroviral therapy for
asymptomatic patients remains uncertain. We assessed the costs-
effectiveness of starting highly active antiretroviral therapy
(HAART) at different CD4 cells counts (main predictors of prog-
nosis) as it emerged from Italian clinical practice in recent years.
METHODS: The study considered 3250 HAART-naïve patients
of the I.CO.N.A. cohort (Italian Cohort Naive Antiretrovirals),
enrolled and followed between 1997 and 2002. In correspon-
dence to >= 500, 350–499 and 200–349 CD4 cells/mm3, we
selected immediate and deferred groups accounting for lead time
bias. To assess the effects of early treatment on AIDS-free sur-
vival, we calculated propensity scores to represent the probabil-
ity of early HAART initiation and then estimated separate Cox
models stratiﬁed on propensity score blocks. The average effects
of early vs. deferred treatment on total health costs were
obtained similarly stratifying by propensity score blocks. The
incremental cost-effectiveness ratio (ICER) and the cost-
effectiveness acceptability curve were also derived. RESULTS:
Adjusted for propensity scores there was no difference in the rate
of AIDS/death in those patients who deferred HAART below 500
or 350 CD4 cells/mm3; we found instead a signiﬁcant difference
for immediate HAART at 200–349 CD4 cells/mm3, with a
hazard ratio of 0.32 (95% CI: 0.17–0.61). The average differ-
ence in total costs across propensity score strata was always
